Yoen-Young Chuah1, Deng-Chyang Wu 2,8, Seng-Kee Chuah3,8, Kuan-Yang Chen4,8 , Chien-Lin Chen5,8 , Chang-Bih Shie6,8, Chih-An Shih7, Ping-I Hsu6,8
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ping Tung Christian Hospital, Ping Tung, Taiwan, 2Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 3Division of Hepato-gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 4Division of Gastroenterology and Hepatology, Department of Internal Medicine, Renai Branch, Taipei City Hospital, Taipei, Taiwan, 5Department of Medicine, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan, 6Department of Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan, 7Division of Gastroenterology, Department of Internal Medicine, Antai Tian-Sheng Memorial Hospital, Antai Medical Care Corporation, Ping-Tung, Taiwan, 8Taiwan Acid-related Disease & Microbiota (TARD-M) Consortium
Background/Aims: REAP-HP study was the pioneer study investigating the expectation and preference of physicians across Asia-Pacific in H pylori eradication in 2015. This study is a follow-up study of REAP-HP in Taiwan.Aims: (1) To investigate the preference in regimens and minimal accepted eradication rate for the first-line anti-H pylori therapy in Taiwan, (2) To survey the most concerned factors when prescribing anti-H pylori regimens in clinical practice, and (3) to compare REAP-HP survey data in 2020 and those surveyed in 2015 regarding the abovementioned end-points.
Methods: A questionnaire for H pylori eradication survey of physicians was distributed to the gastroenterologists who attended Taiwan Digestive Disease Week 2020
Results: A total of 258 physicians from different districts of Taiwan participated in the REAP-HP Survey in 2020. The top three most commonly used anti-H pylori regimens in Taiwan were 14-day standard triple therapy (36.8%), 7-day standard triple therapy (17.8%) and 14-day reverse hybrid therapy (14.7%) respectively compared to the top three most commonly used in Taiwan in 2015 were 7-day standard triple therapy (62%), 14-day standard triple therapy (21%) and 10-day sequential therapy (7%). The minimal accepted eradication rates in northern, central and southern districts of Taiwan were 86.7%, 87.3% and 86.5% respectively in 2020, and 86.6%, 86.2% and 86.5% respectively in 2015. The average minimal accepted eradication rate for first line regimen is 86.7% v.s. 86.5%. The top two most concerned factors during prescribing anti-H pylori therapy were eradication rate and side effect.
Conclusion: 14-day standard triple therapy has replaced 7-day standard triple therapy as the most commonly used first-line anti-H pylori therapy among gastroenterologists in Taiwan in 2020 and 14-day reverse hybrid therapy is on rise to the third place even though the minimal accepted eradication for first line anti- H pylori therapy and the most concerned factor in Taiwan remained the same.
Keywords: Helicobacter Pylori Eradication , REAP-HP, Minimal accepted eradication , Standard triple therapy, Reverse hybrid therapy